This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Enrollment
15
Single dose of 120 mg MK2637 capsules in one of five treatment periods.
Single dose of 50 mg MK2637 capsules in one of five treatment periods.
Single dose of placebo only in one of five treatment periods.
Increase in Motor Evoked Potential (MEP) after dosing with dextromethorphan compared to placebo
Time frame: 5 Hours after initial dosing
Increase in amplitude in the gamma frequency band (24-60 Hz) of resting qEEG after dosing with dextromethorphan compared to placebo
Time frame: 4 Hours after initial dosing
Increase in amplitude in the theta frequency band (4-8 Hz) of resting qEEG after dosing with MK2637 compared to placebo
Time frame: 6.5 hours after initial dosing
Change in Motor Evoked Potential (MEP) after dosing with MK2637 as compared to placebo
Time frame: 5 hours after initial dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.